Aligos Therapeutics Presented Poster Highlighting The Continued Potent Antiviral Activity Of ALG-000184 For Chronic Hepatitis B (CHB) In Both Hbeag-Positive And Hbeag-Negative Subjects At The EASL Congress 2024
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics presented data at the EASL Congress 2024 showing that their drug ALG-000184 demonstrated potent antiviral activity for chronic hepatitis B (CHB) in both HBeAg-positive and HBeAg-negative subjects. The data showed sustained HBV DNA suppression in 90% of HBeAg-positive CHB subjects with no viral breakthrough over 72 weeks.
June 05, 2024 | 7:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aligos Therapeutics presented promising data for their drug ALG-000184 at the EASL Congress 2024, showing sustained HBV DNA suppression in 90% of HBeAg-positive CHB subjects with no viral breakthrough over 72 weeks.
The data presented at the EASL Congress 2024 is highly positive, showing that ALG-000184 is effective in suppressing HBV DNA in a significant portion of patients without viral breakthrough. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100